Revvity, Inc. (RVTY)
NYSE: RVTY · Real-Time Price · USD
91.77
+0.58 (0.64%)
Oct 8, 2025, 4:00 PM EDT - Market closed
Revvity Revenue
Revvity had revenue of $720.28M in the quarter ending June 29, 2025, with 4.13% growth. This brings the company's revenue in the last twelve months to $2.80B, up 3.33% year-over-year. In the year 2024, Revvity had annual revenue of $2.76B with 0.16% growth.
Revenue (ttm)
$2.80B
Revenue Growth
+3.33%
P/S Ratio
3.95
Revenue / Employee
$254,406
Employees
11,000
Market Cap
10.65B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 2.76B | 4.46M | 0.16% |
| Dec 31, 2023 | 2.75B | -561.25M | -16.95% |
| Jan 1, 2023 | 3.31B | -515.99M | -13.48% |
| Jan 2, 2022 | 3.83B | 1.16B | 43.73% |
| Jan 3, 2021 | 2.66B | -220.44M | -7.64% |
| Dec 29, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 3, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
RVTY News
- 2 days ago - Revvity to Hold Earnings Call on Monday, October 27, 2025 - Business Wire
- 6 days ago - Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes - Business Wire
- 9 days ago - Revvity Unveils New AI Software Offering to Transform Preclinical Imaging Analysis - Business Wire
- 16 days ago - Revvity and Profluent Collaborate to Launch AI-Enhanced Adenine Deaminase Pin-point Base Editing Systems - Business Wire
- 4 weeks ago - Revvity, Inc. (RVTY) Presents At Baird 2025 Global Healthcare Conference (Transcript) - Seeking Alpha
- 5 weeks ago - Revvity, Inc. (RVTY) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript - Seeking Alpha
- 5 weeks ago - Revvity Establishes In Vivo Imaging Center of Excellence in North Carolina - Business Wire
- 7 weeks ago - Revvity to Present at Upcoming Investor Conferences - Business Wire